Abstract
The 62 kDa protein product of the c-myc oncogene (p62 c-myc) is thought to be involved in the control of normal cellular proliferation and differentiation. We have measured oncoprotein levels using a flow cytometric assay in 141 operable breast cancers and have correlated levels with prognostic variables, patient survival and disease free intervals. High levels of p62 c-myc were associated with well differentiated tumours. There was no correlation with tumour DNA index, lymph node or oestrogen receptor status. C-myc oncoprotein levels were not predictive of patient survival or disease free interval. This relationship of oncoprotein levels with tumour histological grade is in keeping with the suggestion that the c-myc oncogene is important in the control of cellular differentiation. The other findings imply that measurement of c-myc oncoprotein levels does not yield useful prognostic information.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Locker, A., Dowle, C., Ellis, I. et al. C-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer 60, 669–672 (1989). https://doi.org/10.1038/bjc.1989.337
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.337
This article is cited by
-
Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases—elevated Bmi-1 expression in late breast cancer relapses
Virchows Archiv (2011)
-
MYC oncogenes and human neoplastic disease
Oncogene (1999)
-
Lack of prognostic value of immunoreactivity for p62 oncoprotein in colorectal carcinoma
International Journal of Colorectal Disease (1993)
-
The Nottingham prognostic index in primary breast cancer
Breast Cancer Research and Treatment (1992)